News headlines about LivaNova PLC (NASDAQ:LIVN) have been trending positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. LivaNova PLC earned a news impact score of 0.26 on Accern’s scale. Accern also gave news coverage about the company an impact score of 47.162572462561 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the news articles that may have effected Accern’s rankings:
- Legal & General Group Plc Has $842000 Stake in LivaNova PLC (NASDAQ:LIVN) (footballhebdo.com)
- LivaNova PLC (NASDAQ:LIVN) Hits New 52-Week High on Strong Earnings (overnewsmagazine.com)
- See what the IHS Markit Score report has to say about LivaNova PLC. (finance.yahoo.com)
- LivaNova PLC (NASDAQ:LIVN) Posts Earnings Results, Beats Expectations By $0.19 EPS (americanbankingnews.com)
- LivaNova Reports Second Quarter 2017 Results (enhancedonlinenews.com)
LivaNova PLC (NASDAQ LIVN) traded down 0.66% during midday trading on Friday, reaching $61.78. 347,553 shares of the company’s stock were exchanged. The stock has a market capitalization of $3.02 billion, a price-to-earnings ratio of 110.32 and a beta of 0.62. LivaNova PLC has a 12-month low of $40.83 and a 12-month high of $64.95. The stock’s 50-day moving average is $61.64 and its 200-day moving average is $55.08.
LivaNova PLC (NASDAQ:LIVN) last issued its quarterly earnings results on Wednesday, August 9th. The company reported $1.01 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.82 by $0.19. LivaNova PLC had a net margin of 2.26% and a return on equity of 9.08%. The business had revenue of $321.40 million for the quarter, compared to analyst estimates of $315.75 million. The company’s revenue was up .1% compared to the same quarter last year. On average, equities analysts forecast that LivaNova PLC will post $3.16 earnings per share for the current year.
LIVN has been the subject of a number of research analyst reports. BidaskClub downgraded shares of LivaNova PLC from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 24th. Berenberg Bank reaffirmed a “buy” rating and issued a $70.00 target price on shares of LivaNova PLC in a research report on Friday. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $61.33.
COPYRIGHT VIOLATION NOTICE: “LivaNova PLC (LIVN) Given Daily Media Impact Rating of 0.26” was originally reported by Stock Observer and is the property of of Stock Observer. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://www.thestockobserver.com/2017/08/12/livanova-plc-livn-given-daily-media-impact-rating-of-0-26.html.
In other LivaNova PLC news, Director Alfred J. Novak sold 1,000 shares of the company’s stock in a transaction that occurred on Monday, May 22nd. The shares were sold at an average price of $58.49, for a total transaction of $58,490.00. Following the transaction, the director now owns 12,020 shares in the company, valued at approximately $703,049.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 3,000 shares of company stock worth $180,840 in the last 90 days. 0.28% of the stock is currently owned by company insiders.
LivaNova PLC Company Profile
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Receive News & Ratings for LivaNova PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova PLC and related companies with MarketBeat.com's FREE daily email newsletter.